Glucose intolerance
Drug research and approvals for glucose intolerance: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 177 studies of glucose intolerance are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 177
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
- LIfestyle MEtabotype Study B (LIME-B)NCT07888257 · Not applicable · German Institute of Human Nutrition · starts Oct 26, 2026
- LIfestyle MEtabotype Study ANCT07868601 · Not reported · German Institute of Human Nutrition · starts Oct 10, 2026
- RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGMNCT07861191 · Not reported · National University Health System, Singapore · starts Jul 27, 2026
- Hypothalamic GLP-1 Response in Healthy Weight and ObesityNCT07854886 · Not applicable · University of Copenhagen · starts Oct 1, 2026
- Effects of Hourly Stair-Climbing Exercise Snacks on Metabolic and Vascular Health in Adults With PrediabetesNCT07847684 · Not applicable · St. Louis University · starts Oct 1, 2026
- Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in AgeingNCT07817290 · Not applicable · Azienda Ospedaliero Universitaria Maggiore della Carita · starts Jun 24, 2025
- Georgia CEAL RESTORES Family Diabetes StudyNCT07808723 · Not applicable · Morehouse School of Medicine · starts Aug 29, 2026
- Cardiorespiratory Fitness, Handgrip Strength, and Cardiometabolic Health in Obese Children With or Without Autism…NCT07804680 · Not reported · University of Virginia · starts Aug 5, 2026
Phase 3 5
- LiraglutideGlucagon-like peptide 1 receptor agonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- RamiprilAngiotensin-converting enzyme inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- TadalafilPhosphodiesterase 5A inhibitor
Phase 2 7
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- SitagliptinDipeptidyl peptidase IV inhibitor
- SaxagliptinDipeptidyl peptidase IV inhibitor
- CholecalciferolVitamin D receptor agonist
- TeplizumabT-cell surface glycoprotein CD3 epsilon chain other
- VildagliptinDipeptidyl peptidase IV inhibitor
- Chlorogenic acid
Phase 1 or earlier 4
- PrednisoneGlucocorticoid receptor agonist
- UrsodiolBile acid receptor FXR agonist
- DorzagliatinHexokinase type IV activator
- Quercetin-3'-O-phosphate
How its trials ended
731 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 143 whose ending is known, 50% met their primary endpoint, 13% missed it and 37% stopped early.
- Completed, result not reported31543%
- Ongoing15121%
- Status unknown12217%
- Met its primary endpoint7210%
- Stopped: other or unclear365%
- Missed its primary endpoint182%
- Stopped: enrollment or feasibility71%
- Stopped: funding51%
- Stopped: sponsor or business decision3<1%
- Stopped: lack of efficacy2<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Feb 17, 2012 | KorlymFor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2… | Corcept Therapeutics, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA